For the twelve months ended Sep 30, 2026, Gilead Sciences Inc. reported $30.99B of revenue and -$3.86B of net income.
Revenue, TTM
$30.99B
Revenue growth, YoY
+6.5%
Net income, TTM
-$3.86B
Net margin
-12.5%
Free cash flow, TTM
$13.78B
EPS, diluted, TTM
-$3.15
Cash
$6.44B
Total debt
$26.23B
P/S
6.67
Market cap
$206.55B
Annual revenue$29.44B
FY2016FY2025
Annual net income$8.51B
FY2016FY2025
Annual free cash flow$9.46B
FY2016FY2025
GILD revenue and earnings growth
GILD revenueQ3 2026$8.30B
Quarter YoY
+6.8%
QoQ
+6.4%
FY YoY
+2.4%
5Y CAGR
+3.6%
10Y CAGR
-1.0%
GILD revenue was $8.30B in fiscal Q3 2026 (ended Sep 30, 2026), up 6.8% from a year earlier and up 6.4% from the prior quarter. For the full fiscal 2025 it was $29.44B, up 2.4% from fiscal 2024. Compound annual growth was +3.6% over 5 years and -1.0% over 10 years. It rose in 5 of the last 10 fiscal years.
GILD net incomeQ3 2026$2.43B
Quarter YoY
-20.4%
FY YoY
18x
5Y CAGR
+133.3%
10Y CAGR
-7.3%
GILD net income was $2.43B in fiscal Q3 2026 (ended Sep 30, 2026), down 20.4% from a year earlier. For the full fiscal 2025 it was $8.51B, up about 18-fold from fiscal 2024. Compound annual growth was +133.3% over 5 years and -7.3% over 10 years. It rose in 4 of the last 10 fiscal years.
GILD EPSQ3 2026$1.94
Quarter YoY
-20.2%
FY YoY
18x
5Y CAGR
+132.4%
10Y CAGR
-5.5%
GILD diluted EPS was $1.94 in fiscal Q3 2026 (ended Sep 30, 2026), down 20.2% from a year earlier. For the full fiscal 2025 it was $6.78, up about 18-fold from fiscal 2024. Compound annual growth was +132.4% over 5 years and -5.5% over 10 years.
GILD free cash flowQ3 2026$4.80B
Quarter YoY
+21.1%
QoQ
+39.8%
FY YoY
-8.2%
5Y CAGR
+4.7%
10Y CAGR
-7.4%
GILD free cash flow was $4.80B in fiscal Q3 2026 (ended Sep 30, 2026), up 21.1% from a year earlier and up 39.8% from the prior quarter. For the full fiscal 2025 it was $9.46B, down 8.2% from fiscal 2024. Compound annual growth was +4.7% over 5 years and -7.4% over 10 years. It rose in 3 of the last 10 fiscal years.
Source: XBRL data Gilead Sciences Inc. files with the SEC, latest filing dated Oct 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 2-for-1, first reported Feb 27, 2013.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Gilead Sciences Inc. (GILD) reported $30.99B of revenue for the twelve months ended Sep 30, 2026. That is up 6.5% from the year before. Revenue for fiscal 2025 was $29.44B.
Is GILD profitable?+
No. Gilead Sciences Inc. reported a net loss of $3.86B for the twelve months ended Sep 30, 2026.
How much cash and debt does GILD have?+
Gilead Sciences Inc. reported $6.44B in cash and cash equivalents and $26.23B of debt on its most recent balance sheet in SEC filings.
How fast is GILD revenue growing?+
Gilead Sciences Inc.'s revenue changed +2.4% in fiscal 2025, to $29.44B. Its compound annual growth rate was +3.6% over 5 years and -1.0% over 10 years.
What is GILD gross margin?+
Gilead Sciences Inc.'s gross profit was $24.77B on $30.99B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 79.9%.
What is GILD free cash flow?+
Gilead Sciences Inc. generated $13.78B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $14.48B less capital expenditures.
What is GILD earnings per share?+
Diluted earnings per share were -$3.15 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did GILD last report financial results?+
The latest statements here come from Gilead Sciences Inc.'s 10-Q filed on Oct 30, 2026, covering the period ended Sep 30, 2026.
Where does this GILD financial data come from?+
Quantisnow builds these statements from the structured XBRL data Gilead Sciences Inc. files with the SEC. It is provided for information only and is not investment advice.